Vical, Inc. (NASDAQ:VICL)

I'll go with ZZ on his analysis that Allovectin will fail phase 3... however I like the strong pipeline and after the stock gets cut in half I think it'd be a strong long term buy

joseph714 from the Fool biotech board likes this

Technicals

I feel Vical will outperform with needed cash coming from a vaccine recently licensed to Astellas Pharna of Japan. This will improve their revenue as well as the
balance sheet. A hurdle over the hump. I can see
$5 or more within two quarters. Go go long.

Run down due to de-leveraging of the market, hit $5 on positive news prior to the debt non-sense. Will hit $5 by end of 2011.

Pipeline, pipeline, pipeline- the 3 Ps!

biotech with promising cancer drug in stage III trials

BlackSwanCapital haiku

Third phase data soon

immunotherapeutic

a wunderkind drug

beaten down after last years H1N1 scare, but has opportunity in the viral medicine arena

currently 350 shares in my portfolio.

Unfairly punished for Sanofi's failure (and not Vical's)...

Look for this stock to spike in mid-2011 before results are revealed for the phase III trial of Allovectin-7 in melanoma.

tenmiles

VICL

With many irons in the fire I like their prospects. I really like their emphasis on vaccine production and think that will pan out very well over the next few years.
H1N1 may not have lived up to the hype, but it's only a matter of time before we have a pandemic that does. I think VICL is well positioned for such an event.

@3.41

AS A PHARMACIST I FEEL THE FUTURE IN DRUGS IS IN THE VACINE FIELD, WHICH VICL EXCELS. WITH MONEY FROM MERCK, AND SNY. I FEEL THAT THIS STOCK WILL MOVE UP NEXT YEAR AND FEEL THAT THE SELL OFF THAT IS NOW GOING ON IS A TAX RELIEF SELL OFF.

Good entry point for medical products approved next year.

DNA plasmid technology for pandemic flu (results out in 8/08), peripheral artery disease partnered with ANGES (already approved in Japan) and SNY, Melanoma, CMV, etc. Other iron in fire is Vaxfectin as adjuvant for vaccines. Stock has gone from fantasy land pricing to reality. No current interest with slowly increasing volume and price. Very low capitalization (approximately 140 mm). This is one of those risky biotechs with big up and downside.